Potential Treatment Will Combine Immunotherapy and Chemotherapy

Bristol-Myers Squibb Co. and Celgene Corp. have agreed to collaborate on a clinical study for a potential cancer treatment that will combine immunotherapy and chemotherapy, the companies said Wednesday.

The early-stage study will focus on the treatment's impact on several tumor types, including pancreatic cancer, breast cancer and lung cancer, the companies said.